世界卫生组织粪类圆线虫病公共卫生控制预防性化疗指南解读
粪类圆线虫病估计影响亚洲、非洲、南美和中美洲及太平洋地区3亿至6亿人,可终身感染并在免疫抑制时出现高致死性播散。2024年WHO首次发布指南,条件性推荐在粪类圆线虫感染率≥5%的地区对≥5岁人群单剂伊维菌素(200 μg/kg口服)群体给药。本文总结该推荐、证据、实施考虑和未来研究需求。
要点
- WHO条件性推荐:粪类圆线虫感染率≥5%地区,≥5岁人群单剂伊维菌素200 μg/kg口服群体给药。
- 感染率检测方法为粪便Baermann法或琼脂平板培养法。
- 粪类圆线虫病可终身持续感染,免疫抑制时播散性疾病病死率超过60%。
核心结论
- WHO条件性推荐在粪类圆线虫感染率≥5%的地区对≥5岁所有年龄组单剂伊维菌素(200 μg/kg口服)群体给药以减少粪类圆线虫病。
研究设计与样本
- 本文为2023-24年粪类圆线虫病指南制定组与WHO同事及国际专家共同撰写的综述,总结2024年WHO首版粪类圆线虫病公共卫生控制指南。
主要发现
- 粪类圆线虫病估计影响亚洲、非洲、南美和中美洲及太平洋地区3亿至6亿人。
- 该病可因自身感染而终身持续,免疫抑制时出现过度感染和播散性疾病,病死率超过60%。
- 过去十年关键科学和政策变化及流行国家请求促使WHO将粪类圆线虫病纳入2021-30年路线图及被忽视热带病控制消除目标。
关键数值与推荐
- WHO条件性推荐:在粪类圆线虫感染率≥5%(以粪便Baermann法或琼脂平板培养法检测)的流行地区,对≥5岁所有年龄组单剂伊维菌素(200 μg/kg口服)群体给药以减少粪类圆线虫病。
临床怎么用
- 在粪类圆线虫感染率≥5%的流行地区,可按WHO条件性推荐对≥5岁人群实施单剂伊维菌素(200 μg/kg口服)群体给药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Strongyloidiasis is a soil-transmitted helminthiasis that is estimated to affect 300-600 million people across Asia, Africa, South and central America, and the Pacific. This neglected parasitic disease is most known for its ability to persist as a lifelong infection due to autoinfection and its risk of hyperinfection and disseminated disease during immunosuppression, which has a more than 60% case fatality. Despite the large global burden of strongyloidiasis, there have been no large-scale public health programmes or WHO guidelines directed towards its control and elimination. However, over the past decade, key scientific and policy changes along with requests from endemic countries have led to WHO incorporating strongyloidiasis into its 2021-30 roadmap and public health targets for control and elimination of neglected tropical diseases. In 2024, WHO published its first guideline on public health control of strongyloidiasis with a single recommendation: in endemic settings with a Strongyloides stercoralis infection prevalence of 5% or higher (measured either with Baermann or agar plate culture from stool specimens), WHO conditionally recommends mass drug administration with single-dose ivermectin (200 μg/kg; oral therapy) in all age groups from 5 years and older to reduce strongyloidiasis. This Review, written by the 2023-24 strongyloidiasis guidelines development group along with WHO colleagues and international experts, presents a summary of the recently published WHO guideline recommendation for strongyloidiasis, and the supporting evidence, considerations for public health implementation, and future research needs.
引用
- Lo NC, Addiss DG, Buonfrate D, et al. Review of the WHO guideline on preventive chemotherapy for public health control of strongyloidiasis. Lancet Infect Dis. 2024. PMID: 39481419. doi:10.1016/S1473-3099(24)00595-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。